<DOC>
	<DOCNO>NCT01181050</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial evaluate clinical efficacy single dose NNC0142-0002 administer subject active rheumatoid arthritis ( RA ) .</brief_summary>
	<brief_title>Efficacy NNC0142-0002 Subjects With Rheumatoid Arthritis ( RA )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<criteria>A diagnosis RA meeting American College Rheumatology 1987 ( ACR1987 ) criterion , obtain least three month prior dose trial product Subjects active RA Disease Activity Score ( DAS28CRP ) 4.5 , least five tender five swollen joint ( ) , include one swollen wrist least two swollen ipsilateral metacarpophalangeal ( MCP ) joint ( second fifth ) Concomitant treatment methotrexate ( MTX ) ( 7.525 mg/week ) least 12 week , stable dose least 4 week prior dose Ability examine Magnetic Resonance Imaging ( MRI ) Having fail biologic therapy RA two nonbiologic disease modify antirheumatic drug Chronic inflammatory autoimmune disease RA ( rheumatoid arthritis ) Any ongoing chronic active infectious disease microbial infection require systemic oral intravenous treatment infection within 1 month prior trial start Body mass index ( BMI ) equal 18 equal 40 kg/m^2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>